We forecast that the income of collagen products will grow by 25.78%, 160.00% and 80.00% respectively in 2011-2013, and the company's operating income will increase by 12.57%, 20.26% and 19.69% respectively, corresponding to RMB 0.32,0.47,0.63 yuan in 2011-2013 (calculated on the basis of fully diluted equity without taking into account the impact of net non-operating income). According to accounting standards, weighted by issued equity, the EPS for 2011 is expected to be 0.37 yuan. Considering the obvious release of production capacity after the company's fund-raising project is put into production and the improvement of the current prosperity of the industry, we maintain the recommended rating.
【日信证券】东宝生物:业绩符合预期,胶原蛋白提升业绩
[Nippon Securities] Dongbao Bio: performance meets expectations, collagen improves performance
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.